In case of new-onset atrial fibrillation, patients receiving rivaroxaban in this trial were to increase the daily dose to 20 mg (or 15 mg in the presence of dose-reduction criteria), while patients receiving clopidogrel were to replace the irreversible P2Y12-inhibitor with a VKA in the first 3 months. Here, P2RY12 is linked to atrial fibrillation.